Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Beijing Tiantan Hospital20 enrolled

Overview

1)Preliminarily evaluate the treatment effect of continuous vein injection of recombinant human endostatin on NF2; 2)Preliminarily evaluate the safety and the patient's tolerance of the treatment of endostatin; 3)Provide an objective basis for an enlarged randomized double-blind trial.

Neurofibromatosis type 2 (NF2) is a hereditary tumor predisposition syndrome caused by mutations in the NF2 tumor suppressor gene. Individuals with NF2 have a higher likelihood to develop multiple nervous system tumors, including schwannomas, meningiomas, and ependymomas. The hallmark of NF2 is bilateral vestibular schwannomas. Historically, most NF2 patients experience complete hearing loss either from tumor progression or after treatment of the tumors with surgery or radiation. Effective treatments are urgently needed for NF2 patients with progressive hearing loss because hearing loss is associated with impairment in social, emotional,and communication function and with increased depression. Previous studies of NF2 patients treated with bevacizumab suggested that inhibition of vascular endothelial growth factor (VEGF) could result in hearing improvement and reduction in tumor size.Recombinant human endostatin can inhibit the formation of blood vessels by inhibiting the migration of vascular endothelial cells .In this way, endostatin can inhibit the nutrition of the tumor and decrease the tumor's growth and metastasis. In vitro tests, endostatin can inhibit the cell migration and Tube formation of the microvascular endothelial cell line HHEC. Besides, it can inhibit blood vessels' formation of the chicken embryo sac membrane. Based on these studies, we perform this clinical trial to known the treatment effect and tolerability of endostatin on NF2.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Vestibular Schwannoma Neurofibromatosis Type 2

Interventions

EndostatinDRUG

Method of drug administration:continuous intravenous pumping; Dosage: 7.5mg/m2/d; Course of treatment: 3 months;Total three treatment courses.

Eligibility

Sex: ALLMin age: 16 YearsMax age: 30 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 1)Patients must be at the age of 16-30 * 2)Patients must meet the diagnostic criteria for NF2, with bilateral acoustic neuroma and other central nervous system tumors * 3)Patients must not be treated with other drugs or radiation therapy recently * 4)Patients should live in Beijing or nearby and can be treated in hospital * 5)Patients must be healthy and not be seriously allergic with biological agents * 6)Patients must join the clinical trial voluntarily, with good compliance, cooperate with the researchers well, sign a written informed consent. Exclusion Criteria: * 1)Treated with other drugs, surgery or radiation therapy recently * 2)Brainstem is compressed seriously, with hydrocephalus, need to be treated with surgery in short time * 3)Being pregnant or try to get pregnant, lactating women * 4)With acute or chronic infectious diseases * 5)With heart diseases, cardiac dysfunction or abnormal ECG * 6)With uncontrolled neural or mental diseases, poor compliance * 7)Not available for enhanced MRI * 8)Take part in any other clinical trial * 9)With other conditions that are considered not suitable for this clinical trial.

Locations (1)

Beijing Tiantan Hospital Affiliated to Capital Medical University

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

Change from Baseline in volume of tumour after every course of the treatment

Patients in this clinical trial would receive MRI test to evaluate the volume of tumour after every course of the treatment.

Time frame: Baseline,Month 3,Month 7,Month 11

Secondary Outcomes

Change from Baseline in hearing ability after every course of the treatment

Patients' hearing ability would be tested after every course of the treatment.

Time frame: Baseline,Month 3,Month 7,Month 11

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.